title: Update on clinical research and state of the art management of patients with advanced sarcomas and GIST.
abstract: Sarcomas constitute a rare group of malignancies. According to histology, different treatment options are effective. For gastrointestinal stromal tumours (GISTs), targeted treatment with imatinib controls about 20% of advanced or metastatic disease, whereas chemotherapy is more effective for the rest of the sarcomas. Currently, new targeted treatments are emerging, showing activity in cases resistant to established primary treatment. On the other hand, the exciting results of immunotherapy for other solid tumours, for example, melanoma and lung cancer, make it a promising option in the fight against sarcomas. In this review, we have collected data of established and promising treatments in trials with a view to facilitating the sequencing of sarcoma treatments and for identifying the future of these therapeutic options.
authors.affiliation: Department of Oncology , Kantonsspital Graubünden , Chur , Switzerland.
authors.forename: Yannis
authors.initials: Y
authors.lastname: Metaxas
authors.affiliation: Department of Oncology , Metropolitan Hospital , Athens , Greece.
authors.forename: Georgios
authors.initials: G
authors.lastname: Oikonomopoulos
authors.affiliation: Medical Faculty , University of Ioannina , Ioannina , Greece.
authors.forename: George
authors.initials: G
authors.lastname: Pentheroudakis
keywords: Sarcoma, GIST, update,; treatment